MedTrace Logo

Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma

NCT02928510 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2021-07-14

No results posted yet for this study

Summary

This research trial studies the mechanisms of idelalisib-associated diarrhea in patients with chronic lymphocytic leukemia, indolent non-hodgkin lymphoma, or small lymphocytic lymphoma that has come back after a period of improvement. The cancer treatment drug idelalisib triggers diarrhea in some patients. Studying stool, blood, and tissue samples in the lab from patients who are given idelalisib may help doctors learn more about the side effects and may help to treat them in future patients.

Conditions

  • Absence of Signs or Symptoms
  • B-Cell Non-Hodgkin Lymphoma
  • Digestive System Signs and Symptoms
  • Indolent Adult Non-Hodgkin Lymphoma
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • Recurrent Chronic Lymphocytic Leukemia
  • Recurrent Indolent Adult Non-Hodgkin Lymphoma
  • Recurrent Small Lymphocytic Lymphoma

Interventions

PROCEDURE

Biospecimen Collection

Undergo biospecimen collection

PROCEDURE

Colonoscopy

Undergo colonoscopy

PROCEDURE

Colposcopic Biopsy

Undergo colposcopic biopsy

DRUG

Idelalisib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

PROCEDURE

Physical Examination

Undergo physical examination

PROCEDURE

Sigmoidoscopy

Undergo sigmoidoscopy

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • Jonsson Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Daniel Hommes · UCLA / Jonsson Comprehensive Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-01
Primary Completion
2018-06-05
Completion
2018-06-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02928510 on ClinicalTrials.gov